Cell cycle dependence of boron uptake from two boron compounds used for clinical neutron capture therapy
Introduction
Tumor cells in host tissues have a high mitotic index. However, tumor cells are not always in the growth phase. Many cells enter into a quiescence phase because of hypoxia, under nutrition due to poor vascularization, or other reasons [1].
In boron neutron capture therapy (BNCT), due to the short range of alpha particles (about 10 mm), only the cells that incorporate the boron compound are selectively injured. Accordingly, it is desirable for boron to be taken up by all neoplastic cells. In previous investigations, the main issue was the difference in boron uptake between normal and neoplastic cells. Recently, the attention has focused on the differences in uptake by tumor cells in different phases of the cell cycle.
Masunaga et al. [2], [3] showed, based on indirect measurements, that the differences in the radiobiological effects of quiescent cells and growth-phase cells were particularly large between boronophenylalanine (BPA) and sodium borocaptate (BSH).
In this study, we directly measured the boron concentration in cells in different phase of the cell cycle.
Section snippets
Cell lines
V79 is a cell line of Chinese hamster lung origin. SCCVII is a mouse squamous cell carcinoma, and C6 is a rat glioma cell line. Each cell line was cultured with Earl's minimum essential medium (MEM) (SIGMA-Aldrich Japan, Tokyo, Japan) supplemented with 10% fetal bovine serum. The cell lines were maintained at 37°C in an atmosphere of 5% CO2 in air.
Measurement of doubling time
A total of 2.5×105 cells of each cell line were seeded on a 6-cm-diameter petri dish containing 5 ml MEM, and incubated for 0–80 h at 37°C.
Boron compounds
BSH (Boron
Cell growth and doubling time
Fig. 1 shows the growth curve of each cell line. The doubling time was 12.5 h for C6 and V79, and 17.7 h for SCCVII. As shown in Fig. 1, the cell started to multiply 24 h after they were seeded.
Boron uptake
The boron uptake from BSH and BPA as a function of time is shown in Fig. 2. The uptake of boron from BSH did not change much, but in the case of BPA the concentration of boron increased as a function of time. The level of boron uptake in the BPA group was three or four times higher than in the BSH group
Discussion
In BNCT, two boron compounds, BSH and BPA, have been used. BSH is known to accumulate in tumor cells only and is scarcely measurable in the normal brain, but the blood boron concentration to tumor blood concentration ratio is reported to be around 1 depending on the tumor sample [5], [6]. On the other hand, BPA accumulates in tumor cells and also in the normal brain with an uptake ratio of about 3:1. Considering the treatment of malignant gliomas with BNCT, in the case of BSH, the boron in the
References (14)
- et al.
Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy
Int. J. Radiat. Oncol. Biol. Phys
(1996) - et al.
Protein measurement with the folin phenol reagent
J. Biol. Chem.
(1951) - et al.
Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood–brain barrier disruption
Int. J. Radiat. Oncol. Biol. Phys.
(1997) - et al.
Derivations of relative biological effectiveness for the high-LET radiations produced during boron neutron capture irradiations of the 9L rat gliosarcoma in vitro and in vivo
Int. J. Oncol. Biol. Phys.
(1993) - et al.
The combined effect of boronophenylalanine and borocaptate in boron neutron capture therapy for SCCVII tumors in mice
Int. J. Radiat. Oncol. Biol. Phys.
(1999) The problem of the quiescent cancer cell
Adv. Enzyme Regul.
(1989)- et al.
Evaluation of response to thermal neutron irradiation in quiescent cell populations within murine solid tumors using micronucleus assay
Annu. Rep. Res. Reactor Inst. Kyoto Univ.
(1995)
Cited by (48)
Targeted strategies to deliver boron agents across the blood–brain barrier for neutron capture therapy of brain tumors
2024, International Journal of PharmaceuticsBNCT for primary synovial sarcoma
2021, Applied Radiation and IsotopesBoron neutron capture therapy for clear cell sarcoma
2020, Applied Radiation and IsotopesPreclinical study of boron neutron capture therapy for bone metastasis using human breast cancer cell lines
2020, Applied Radiation and IsotopesCitation Excerpt :In contrast, the distribution of 10B in the pathological fracture BNCT group might be heterogeneous, caused by an increase in blood flow due to the fracture. This fact could explain why some tumor cells survived after BNCT, possibly owing to the insufficiency of 10B uptake, which is attributed to LAT1 expression (Wongthai et al., 2015) and the cell cycle-dependency of tumor cells (Yoshida et al., 2002) and/or the presence of quiescent tumor cells (Masunaga and Ono, 2002). Although the clinical treatment of choice for bone metastasis from breast cancer comprises antiresorptive agents, radiopharmaceuticals, radiation therapy, and surgery, bone metastasis of the tumor often occurs in the terminal phase and the disease is difficult to control because it has acquired resistance to radiation and anticancer drugs.
Boron analysis and imaging of cells with 2-hr BPA exposure by using micro-proton particle-induced gamma-ray emission (PIGE)
2020, Applied Radiation and IsotopesCitation Excerpt :Micro-PIXE/PIGE may therefore have the potential for tissue sample analysis (Bortolussi and Altieri, 2013). Yoshida et al. (2002) reported that cellular boron concentration is dependent on the cell cycle and the BPA exposure time. A tendency of increased boron concentration was revealed in the 24 h time course since cells cultured with a BPA solution at 60 μg10 B/mL for 3 h showed a boron concentration of 50–100 ng/106 cells.
Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS
2015, Applied Radiation and Isotopes